Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, which speaks to the promise of the FDA-approved garadacimab.
Timothy Craig, DO
Advertisement
Professor, Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, and Professor, Department of Pediatrics at Penn State University
Articles by Timothy Craig, DO
The recent approval of garadacimab can help to treat patients with hereditary angioedema (HAE) along with sebetralstat, which is awaiting FDA approval, explains Timothy Craig, DO, Penn State Health.
With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
4
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
5
